Tel: 0755-85269922 E-mail: sales@biochemmall.com
ICP:粤ICP备19135875号
Description: Capmatinib (formerly also known as INCB-28060; INC280; Tabrecta) is a novel, potent, orally bioavailable, ATP-competitive inhibitor of c-MET with potential antitumor activity. It inhibits c-MET with an IC50 of 0.13 nM in a cell-free assay, and is inactive against RONβ, as well as EGFR and HER-3. Capmatinib has gained approval for the treatment of adults with metastatic non-small cell lung cancer. c-Met inhibitor INC280 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein.
Attribute [Chem Name] Capmatinib [Synonym] Capmatinib; INC280, INCB 28060; NVP-INC280; INC 280; INCB028060; NVP INC280; INCB28060; INCB-28060; NVPINC280; INC280; INC-280; INCB-028060; INCB 028060; [CAS No.] 1029712-80-8 [Formula] C23H17FN6O [Molecular] 412.42 [Storage] Sealed storage
Goods Tag